Table 4 Fever and parasite clearance reported in efficacy studies in Ethiopia (2004–2020)
Study | Patient Enrolled (N) | Patient available | Patient Included | Fever clearance (%) | Parasite clearance (%) | Supervised | ||||
|---|---|---|---|---|---|---|---|---|---|---|
D1 | D2 | D3 | D1 | D2 | D3 | |||||
Abamecha et al. [35] | 80 | 76 | 72 | 52.5 | 87.2 | 97.5 | 61.2 | 81.2 | 96.2 | Partial |
Teklemariam et al. [44] | 92 | 79 | 78 | 80.0 | 97.8 | 100.0 | 33.0 | 84.4 | 100.0 | Partial |
Deressa et al. [42] | 80 | 75 | 69 | 62.5 | 93.7 | 97.5 | 67.5 | 85.0 | 95.0 | Partial |
Nega et al. [39] | 91 | 85 | 83 | 78.7 | 94.3 | 97.7 | 69.7 | 95.5 | 100.0 | Partial |
Wudneh et al. [49] | 91 | 81 | 80 | 69.6 | 97.8 | 100.0 | 23.6 | 91.0 | 100.0 | Partial |
Kanche et al. [48] | 88 | 86 | 86 | N/R | 59.1 | 93.2 | N/R | 72.2 | 94.3 | Partial |
Mekonnen et al. [38] | 93 | 89 | 84 | 88.1 | 94.4 | 100.0 | 88.8 | 96.6 | 100.0 | Partial |
Ebstie et al. [47] | 134 | 130 | 128 | NR | NR | 87.9 | NR | 85.9 | 96.1 | Partial |
Getnet et al. [40] | 80 | 80 | 74 | 75.0 | 91.3 | 96.2 | 73.8 | 91.3 | 94.9 | Partial |
Mulu et al. [45] | 66 | 60 | 58 | 89.4 | 98.5 | 100.0 | 84.8 | 93.9 | 100.0 | NR |
Eshetu et al. [36] | 348 | 315 | 312 | NR | 96.7 | 99.1 | NR | 98.2 | 99.4 | Non-supervised |
Kinfu et al. [43] | 73 | 71 | 69 | NR | NR | 100.0 | NR | 100.0 | 100.0 | Partial |
Hwang et al. [37] | 119 | 112 | 111 | 65.2 | 90.5 | 93.0 | NR | 93.1 | 99.1 | Partial |
Assefa et al. [41] | 90 | 82 | 79 | NR | NR | 100 | 98 | NR | 100.0 | Partial |
Kefyalew et al. [46] | 102 | 102 | 102 | 44.1 | 82.4 | 93.1 | NR | NR | NR | Partial |